SHORT REPORT
Endomyocardial biopsy: a 21st century diagnostic tool
 
More details
Hide details
1
Pathology and Histology, Faculty of Life Sciences, University of Madeira, Portugal
 
2
Clinical and Anatomical Pathology Laboratory (LANA), Funchal, Madeira, Portugal
 
3
Pathology, Hospital de Santa Cruz – CHLO, Lisboa, Portugal
 
4
Cardiology, Hospital de Santa Cruz – CHLO, Lisboa, Portugal
 
 
Submission date: 2022-01-01
 
 
Acceptance date: 2022-01-06
 
 
Publication date: 2022-03-08
 
 
Pol J Pathol 2021;72(4):356-357
 
KEYWORDS
TOPICS
ABSTRACT
The question of the utility of Endomyocardial Biopsy (EMB) often and recurrently raises.
It is claimed that the image techniques provide identical results without the risks of an invasive procedure. It is a fact that the impressive technico-scientific development of cardiovascular imagological methodologies covers a broad spectrum of diagnosis. It is also a fact that endomyocardial biopsy is not completely risk-free. Yet, when performed by experienced professionals in reference centres, endomyocardial biopsies my disclose a final unexpected nosologic entity, confirm or exclude a proposed diagnosis and, even when not showing specific lesions in the examined samples, EMB may point to a multifocal involvement of the heart that eventually skipped the fragments collected [1, 2, 3].
REFERENCES (11)
1.
Veinot J. Endomyocardial Biopsy – when and how? Cardiovascular Pathology 2011; 20: 291-296.
 
2.
Nguyen CT, Lee E, Luo H, et al. Echocardiographic guidance for diagnostic and therapeutic percutaneous procedures. Cardiovasc Diagn Ther 2011; 1: 11-36.
 
3.
Gupta A, Aghdssi A. Endomyocardial Biopsy: Examining Indications and Trends in Use – More Native Heart Biopsy to Come? Cardiology 2019; 142: 102-104.
 
4.
Nair V, Butany J. Heart transplant biopsies: interpretation and significance. J Clin Pathol 2010; 63: 12-20.
 
5.
Gouveia RH, Vitorino E, Ramos S et al. C4d – The Witness of Humoral Rejection. Transplantation Proceedings 2009; 41: 866-867.
 
6.
Moonen M, Lancellotti P. La Myocardite. Rev Med Liège 2018; 73: 269-276.
 
7.
Zhou Z, Lopez H, Pérez G, et al. Toxoplasmosis and the Heart. Curr Probl Cardiol 2021; 46: 100741.
 
8.
Ash S, Shorer E, Ramgobin D, et al. Cardiac amyloidosis –.
 
9.
A review of current literature for the practicing physician. Clin Cardiol 2021; 44: 322-331.
 
10.
Yamamoto H, Yockochi T. Transtherytin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Failure 2019; 6: 1128-1139.
 
11.
Martino A, Re F, Barzaghi C et al. Occult primary cardiac lymphomas causing unexpected/sudden death or acute heart failure. Virchows Arch 2020; 477: 603-607.
 
eISSN:2084-9869
ISSN:1233-9687
Journals System - logo
Scroll to top